Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock

Critical Care Medicine

Volumn 33, Issue 3, 2005, Pages 564-573

  Sundén Cullberg, Jonas ^a   Norrby Teglund, Anna ^a   Rouhiainen, Ari ^b,c   Rauvala, Heikki ^b   Herman, Gunilla ^a   Tracey, Kevin J ^d   Lee, Martin L ^e   Andersson, Jan ^a   Tokics, Leif ^a   Treutiger, Carl Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF HELSINKI   (Finland)

^c FINNISH RED CROSS BLOOD SERVICE   (Finland)

^d N Shore Long Isl Jewish Res Inst ^*  (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytokine; High mobility group box 1 protein; Inflammation; Sepsis related Organ Failure Assessment score; Septic shock; Severe sepsis

Indexed keywords

AUTACOID; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD SAMPLING; CELL INCLUSION; CELL KINETICS; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DISEASE SEVERITY; EVALUATION; FEMALE; FUNCTIONAL ASSESSMENT; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; MALE; MULTIPLE ORGAN FAILURE; OUTPATIENT DEPARTMENT; POPULATION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN SECRETION; SCORING SYSTEM; SEPSIS; SEPTIC SHOCK; UNIVERSITY HOSPITAL;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HEALTH STATUS INDICATORS; HMGB1 PROTEIN; HUMANS; INFLAMMATION; MALE; PROSPECTIVE STUDIES; SEPSIS; SHOCK, SEPTIC; SWEDEN;

EID: 20144380566     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000155991.88802.4D     Document Type: Article

References (29)

1. Angus DC, Linde-Zwirble WT, Lidicker J et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
2. Friedman G, Silva E, Vincent JL: Has the mortality of septic shock changed with time? Crit Care Med 1998; 26:2078-2086
3. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
4. Annane D, Sebille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871
5. van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-1367
6. Rivers E, Nguyen B, Havstad S, et al: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377
7. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al: Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991; 324:429-436
8. Fisher CJ Jr, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334:1697-1702
9. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273:934-941
10. Fisher CJ, Slotman GJ, Opal SM, et al: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study Group. Crit Care Med 1994; 22:12-21
11. 2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32:2173-2182
12. Wang H, Bloom O, Zhang M, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285:248-251
13. Bustin M: Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999; 19:5237-5246
14. Rauvala H, Pihlaskari R: Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J Biol Chem 1987; 262:16625-16635
15. Merenmies J, Pihlaskari R, Laitinen J, et al: 30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J Biol Chem 1991; 266:16722-16729
16. Rauvala H, Merenmies J, Pihlaskari R, et al: The adhesive and neurite-promoting molecule p30: Analysis of the amino-terminal sequence and production of antipeptide antibodies that detect p30 at the surface of neuroblastoma cells and of brain neurons. J Cell Biol 1988; 107:2293-2305
17. Parkkinen J, Raulo E, Merenmies J, et al: Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J Biol Chem 1993; 268:19726-19738
18. Yang H, Ochani M, Li J, et al: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 2004; 101:296-301
19. Abraham E, Arcaroli J, Carmody A, et al: HMG-1 as a mediator of acute lung inflammation. J Immunol 2000; 165:2950-2954
20. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655
21. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
22. Vincent JL, Moreno R, Takala J, et al: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/ failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707-710
23. Rouhiainen A, Imai S, Rauvala H, et al: Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost 2000; 84:1087-1094
24. Winer BJ, Brown DR, Michels KM. Statistical Principles in Experimental Design. Third Edition. New York, McGraw-Hill, 1991, p 254
25. Ortqvist A, Kalin M, Julander I, et al: Deaths in bacteremic pneumococcal pneumonia. A comparison of two populations - Huntington, WVa, and Stockholm, Sweden. Chest 1993; 103:710-716
26. Darenberg J, Ihendyane N, Sjolin J, et al: Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: A European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37:333-340
27. Angus DC, Wax RS: Epidemiology of sepsis: An update. Crit Care Med 2001; 29(7 suppl):S109-S116
28. Alberti C, Brun-Buisson C, Burchardi H, et al: Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002; 28:108-121
29. Schroder J, Kahlke V, Staubach KH, et al: Gender differences in human sepsis. Arch Surg 1998; 133:1200-1205